NCT07427251RecruitingPhase 4
The Postprandial Hypo-Avoid Study
Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The objective of the study is to evaluate whether pre-exercise administration of low-dose subcutaneous glucagon prevents or attenuates exercise-induced declines in plasma glucose concentration during and after moderate-intensity continuous exercise (MICE) performed approximately 90 minutes after a meal in adults with type 1 diabetes using an automated insulin delivery (AID) system. The primary endpoint is the difference in the change in plasma glucose (PG) from exercise initiation to the nadir during exercise and through the 2-hour post-exercise period between the glucagon (GCN) and carbohydrate (CHO) visits.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 16 Feb 2026
- Start date
- 27 Apr 2026
- Primary completion date
- 1 May 2027
- Lead sponsor
- Steno Diabetes Center Copenhagen
- Diseases
- Type 1 diabetes
- NCT number
- NCT07427251
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 18
- From 27 Apr 2026 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (methods are considered adequate for study enrolment for females: an intrauterine device, hormonal contraception (birth control pills, implant, patch, vaginal ring or injection), a single partner who is sterile or infertile, or sexual abstinence. Contraception is required throughout the study duration. Sterilized or postmenopausal women (\>12 months since last period) are not required to use contraception)
Other illness
- Allergies to lactose or glucagon
- Known or suspected allergies to glucagon or related products
- History of hypersensitivity or allergic reaction to glucagon or lactose
Lab values
- Concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation
Other
- Patients with diagnosed pheochromocytoma, insulinoma or gastroparesis
- Lack of compliance with key study procedures at the discretion of the investigator
- Inability to understand the individual information and to give informed consent
Who the study is looking for
- Age ≥ 18 years
- Type 1 diabetes ≥ 2 years
- Using an automated insulin delivery system for ≥ 3 months
- NovoRapid or Fiasp use ≥1 week
- Proficiency in carbohydrate counting
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Steno Diabetes Center Copenhagen Coordinator of this site? Confirm its status | Herlev | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.